Clinical Utility of Target Selector™ ctDNA Testing: Detection of EGFR Mutations via Liquid Biopsy Enabled Targeted Therapy Selection for Patients with Advanced NSCLC

Veena M Singh^1*, Rodrigo Erlich^2,3 and Cecile Rose T Vibat¹

¹Biocept, Inc., 5810 Nancy Ridge Drive, San Diego, CA,, United States

²Bay Hematology Oncology, 8221 Teal Drive, Suite 302, Easton, Maryland, USA

³Cornell University, Memorial Sloan Kettering Cancer Center, New York, USA

^*Corresponding Author: Veena M Singh, MD, FCAP, FACMG Biocept, Inc., 5810 Nancy Ridge Drive San Diego, CA, 92121, United States, Tel: 858-204-3649, Fax: 858-320-8261 Email:

Received Date: Oct 17, 2018 / Accepted Date: Oct 26, 2018 / Published Date: Nov 10, 2018